triazoles has been researched along with Tumour Lysis Syndrome in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 2 (66.67) | 2.80 |
Authors | Studies |
---|---|
Chen, TT; Cheng, FM; Lin, CC; Tien, JZ; Yeh, SP | 1 |
Castellon, C; Chaquette, R; Meleveedu, KS; Onkarappa Mangala, Y; Perez Rodriguez, A | 1 |
Abe, M; Fujii, S; Harada, T; Jinno, T; Kagawa, K; Matsumoto, T; Miki, H; Nakamura, S; Nakano, A; Ozaki, S; Takeuchi, K; Yata, K | 1 |
3 other study(ies) available for triazoles and Tumour Lysis Syndrome
Article | Year |
---|---|
Venetoclax plus cytochrome P450 inhibitors without ramp-up strategy led to low risk of tumor lysis syndrome in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Child; Creatinine; Cytochrome P-450 Enzyme Inhibitors; Drug Administration Schedule; Drug Synergism; Female; Humans; Hyperuricemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Sulfonamides; Triazoles; Tumor Lysis Syndrome; Urate Oxidase; Uric Acid; Young Adult | 2020 |
First case report of tumor lysis syndrome and acute renal failure after selinexor use in multiple myeloma.
Topics: Acute Kidney Injury; Humans; Hydrazines; Multiple Myeloma; Triazoles; Tumor Lysis Syndrome | 2021 |
[Multiple myeloma complicated with disseminated zygomycosis after bortezomib therapy].
Topics: Acidosis; Aged; Antifungal Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Echinocandins; Fatal Outcome; Humans; Lipopeptides; Male; Micafungin; Multiple Myeloma; Pyrazines; Pyrimidines; Triazoles; Tumor Lysis Syndrome; Voriconazole; Zygomycosis | 2010 |